Results 121 to 130 of about 1,629 (148)

Challenges and practical considerations in the management of blastic plasmacytoid dendritic cell neoplasm: A single-center experience. [PDF]

Leuk Res Rep
Andanamala H, Pemmaraju N, Al-Juhaishi T.   +2 more
europepmc   +1 more source

Blastic plasmacytoid dendritic cell neoplasm in Jinhua, China: Two case reports. [PDF]

World J Clin Cases
Cai JW, Li MY, Wang WH, Shi HQ, Yang YH, Chen JJ.   +5 more
europepmc   +1 more source

A rare case of Blastic plasmacytoid dendritic cell neoplasm with gynecologic presentation. [PDF]

Leuk Res Rep
Khouloud M, Nader S, Ahlem B, Ines S, Montacer H, Rayhan C.   +5 more
europepmc   +1 more source

Advancing the understanding and management of blastic plasmacytoid dendritic cell neoplasm: Insights from recent case studies. [PDF]

World J Clin Cases
Luo Y, Wang LJ, Wang CL.
europepmc   +1 more source

Spontaneous Remission of Blastic Plasmacytoid Dendritic Cell Neoplasm: A Case Report. [PDF]

Medicina (Kaunas)
Castaño-Bonilla T, Mata R, Láinez-González D, Gonzalo R, Castañón S, Díaz de la Pinta FJ, Blas C, López-Lorenzo JL, Alonso-Domínguez JM.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Blastic Plasmacytoid Dendritic Cell Neoplasm

Journal of the National Comprehensive Cancer Network, 2023
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy with an aggressive clinical course and poor prognosis. BPDCN is most often characterized by its presentation with distinct cutaneous lesions. Bone marrow involvement, lymphadenopathy, splenomegaly, and/or cytopenias are also seen to varying degrees.
Akriti, Jain, Kendra, Sweet
  +5 more sources

Blastic Plasmacytoid Dendritic Cell Neoplasm

The American Journal of Dermatopathology, 2021
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy that frequently has cutaneous manifestations. The diagnosis can be a challenge because of its heterogenous clinical presentation, ranging from a brown or violaceous solitary nodule or patch to mixed, disseminated lesions.
Ather, Adnan, Priscilla R, Powell, Cecil Jordan, Staples, Bradley, Evanson, Palak K, Parekh   +4 more
openaire   +3 more sources

Blastic Plasmacytoid Dendritic Cell Neoplasm in Children

Hematology/Oncology Clinics of North America, 2020
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive hematological malignancy, derived from plasmacytoid dendritic cells. It mainly occurs in older adults, but has been reported across all age groups. Most patients present with skin lesions with or without marrow involvement and leukemic dissemination.
Yixian, Li, Victoria, Sun, Weili, Sun, Anna, Pawlowska   +3 more
openaire   +2 more sources

Tagraxofusp for Blastic Plasmacytoid Dendritic Cell Neoplasm

Hematology/Oncology Clinics of North America, 2020
Tagraxofusp, a CD123-targeted immunotoxin, is the first FDA-approved treatment for patients 2 years and older with blastic plasmacytoid dendritic cell neoplasm (BPDCN). It has been shown to be safe and effective in treatment-naïve and previously treated adult patients, with high rates of successful bridging to hematopoietic stem cell transplantation ...
Danielle, Hammond, Naveen, Pemmaraju
openaire   +2 more sources

Blastic plasmacytoid dendritic cell neoplasm

Hematology Meeting Reports, 2009
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare haematological malignancy characterized by the clonal proliferation of immature or precursors of plasmacytoid dendritic cells (PDC), also known as professional type I interferon producing cells.1 This neoplasm was originally recognized in 19942 and the uncertainty regarding its histogenesis
F Facchetti, M Ungari, D Marocolo, S Lonardi, W Vermi   +4 more
openaire   +1 more source